Teleflex Incorporated (NYSE:TFX) – Analysts at William Blair issued their Q1 2018 earnings per share (EPS) estimates for Teleflex in a research note issued to investors on Saturday. William Blair analyst B. Weinstein expects that the medical technology company will earn $1.95 per share for the quarter. William Blair also issued estimates for Teleflex’s Q2 2018 earnings at $2.45 EPS, Q3 2018 earnings at $2.50 EPS and Q4 2018 earnings at $2.67 EPS.
Several other brokerages have also weighed in on TFX. Leerink Swann restated a “buy” rating and issued a $321.00 price target (up previously from $307.00) on shares of Teleflex in a research note on Tuesday, January 30th. Stephens restated a “buy” rating and issued a $300.00 price target on shares of Teleflex in a research note on Thursday, January 18th. TheStreet lowered Teleflex from an “a-” rating to a “c+” rating in a research note on Monday, March 12th. Finally, ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. Teleflex currently has an average rating of “Hold” and an average price target of $281.56.
Teleflex (NYSE TFX) opened at $260.05 on Tuesday. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 0.89. Teleflex has a 52 week low of $191.04 and a 52 week high of $288.78. The firm has a market capitalization of $11,809.22, a PE ratio of 79.53, a P/E/G ratio of 1.94 and a beta of 1.22.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $0.04. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The firm had revenue of $595.10 million during the quarter, compared to analyst estimates of $601.17 million. During the same quarter in the previous year, the business earned $2.13 EPS. Teleflex’s revenue for the quarter was up 15.8% compared to the same quarter last year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Friday, March 2nd were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.52%. The ex-dividend date was Thursday, March 1st. Teleflex’s payout ratio is 41.59%.
In related news, Director George Babich, Jr. sold 2,500 shares of Teleflex stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $263.38, for a total value of $658,450.00. Following the sale, the director now directly owns 10,583 shares in the company, valued at approximately $2,787,350.54. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total value of $49,792.00. Following the completion of the sale, the director now owns 8,080 shares in the company, valued at $2,011,596.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,259 shares of company stock worth $3,760,536. 2.39% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Teleflex by 3.4% during the 4th quarter. BlackRock Inc. now owns 4,709,341 shares of the medical technology company’s stock worth $1,171,779,000 after purchasing an additional 156,527 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Teleflex by 24.1% during the 4th quarter. American Century Companies Inc. now owns 1,474,609 shares of the medical technology company’s stock worth $366,912,000 after purchasing an additional 286,700 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Teleflex by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 398,866 shares of the medical technology company’s stock worth $99,192,000 after purchasing an additional 9,515 shares during the last quarter. William Blair Investment Management LLC acquired a new position in shares of Teleflex during the 4th quarter worth approximately $53,163,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Teleflex by 511.6% during the 4th quarter. Renaissance Technologies LLC now owns 195,700 shares of the medical technology company’s stock worth $48,694,000 after purchasing an additional 163,700 shares during the last quarter. Institutional investors own 90.75% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Teleflex Incorporated (TFX) Forecasted to Post Q1 2018 Earnings of $1.95 Per Share” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/22/teleflex-incorporated-tfx-forecasted-to-post-q1-2018-earnings-of-1-95-per-share.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.